OUR WORK

Portfolio of marketed products enhanced by late-stage clinical pipeline

Uni-Bio Science has developed a strong competitive portfolio of market-leading products in diabetes, ophthalmology and dermatology across China. We are also committed to developing next-generation innovative therapies and have a growing pipeline of drug candidates with €œ'blockbuster'€ potential that are complementary to our existing portfolio. We are focused on broadening our portfolio through our dual-pronged strategy to research and develop new medicines in-house and through strategic in-licensing. We apply a strict criteria to identifying 'new candidates' all must address a significant medical need in Chinese healthcare and demonstrate a strong market access positioning. Our products are manufactured at our state-of-the-art cGMP certified plants in Beijing and Shenzhen.

Focused on the discovery and development of innovative therapies :

• 

Addressing large patient groups

• 

Providing a solution to an unmet medical need

• 

Demonstrating clear clinical advantage

• 

Potentially best- or first-in-class

• 

Uni-Bio Science has developed a well-balanced proprietary biologics franchise

• 

Uni-Bio Science’s current sales portfolio has a strong market access position

• 

Uni-bio Science is one of the very few regional biotech players to have successfully developed new drugs through clinical pipeline

• 

Winner of “Best Innovation –Pharmaceutical” HKB Award 2015